Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. - Weinstock-Guttman B; Bermel R; Cutter G; Freedman MS; Leist TP; Ma X; Kile D; Musch B; Reder AT; Wolinsky JS (Multiple sclerosis (Houndmills, Basingstoke, England), 2022)